More recently, third-generation TKIs, such as Osimertinib, have shown a significant improvement in progression-free survival and overall survival [77], thus becoming the front-line therapy for patients with EGFR-mutated NSCLC [78]. Here, EGFR is linked to non-small cell lung carcinoma.